Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   43207   clinical trials with a EudraCT protocol, of which   7151   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-000047-31
    Sponsor's Protocol Code Number:AMT-101-202
    National Competent Authority:Germany - BfArM
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2020-08-17
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedGermany - BfArM
    A.2EudraCT number2020-000047-31
    A.3Full title of the trial
    A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Subjects with Moderate to Severe Ulcerative Colitis
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study of AMT-101 in patients with Ulcerative Colitis.
    A.4.1Sponsor's protocol code numberAMT-101-202
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorApplied Molecular Transport Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportApplied Molecular Transport Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationApplied Molecular Transport Inc.
    B.5.2Functional name of contact pointClinical Trial AMT-101-202
    B.5.3 Address:
    B.5.3.1Street Address1 Tower Place, Suite 850
    B.5.3.2Town/ citySouth San Francisco
    B.5.3.3Post codeCA 94080
    B.5.3.4CountryUnited States
    B.5.4Telephone number1650392 0420
    B.5.6E-mailCT101@appliedmt.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAMT-101
    D.3.4Pharmaceutical form Gastro-resistant tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNot yet assigned
    D.3.9.3Other descriptive nameAMT-101
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number3
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboGastro-resistant tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Ulcerative Colitis
    E.1.1.1Medical condition in easily understood language
    Ulcerative colitis is a form of inflammatory bowel disease (IBD) that causes inflammation and ulcers in the colon resulting in abdominal pain and bloody diarrhea
    E.1.1.2Therapeutic area Diseases [C] - Digestive System Diseases [C06]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level LLT
    E.1.2Classification code 10045365
    E.1.2Term Ulcerative colitis
    E.1.2System Organ Class 100000004856
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To assess the efficacy of repeated oral doses of AMT-101 versus placebo to reduce Mayo Endoscopic Subscore (MES) at Week 12 in adult subjects with moderate to severe UC
    E.2.2Secondary objectives of the trial
    Secondary Objectives:
    - To evaluate the effects of AMT-101 on disease activity as measured by symptoms, endoscopy, histology, and biomarkers over 12 weeks
    - To evaluate safety and tolerability of oral AMT-101 over 12 weeks
    - To assess the pharmacokinetic (PK) parameters of AMT-101
    - To assess health-related quality of life (HRQOL)

    Exploratory Objectives:
    - To assess the pharmacodynamic (PD) effect of AMT-101 on inflammation
    - To assess the PK parameters of AMT-101 in mucosal tissue
    - To assess the PD effect of AMT-101 on biomarkers
    - To assess target engagement and mechanism of action
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    The study will enroll male and female adult subjects with moderate to severe UC.

    Inclusion criteria (subjects must meet the following criteria to be randomized into the study):
    1. Male and female subjects aged 18 to 75 years, inclusive.
    2. Diagnosis of UC for at least 3 months prior to screening.
    3. Moderate to severe UC, as defined by a total MCS of 6 to 12 inclusive at baseline, with a MES ≥ 2 (confirmed by central reader).
    4. If subjects have previously received any biologic (i.e., tumor necrosis factor [TNF] antagonists, vedolizumab, ustekinumab) or tofacitinib therapy, they must meet the following:
    a. Biologics: a washout period of at least 12 weeks or 5 half-lives prior to randomization, or a washout period of at least 4 weeks prior to randomization if biologic drug levels are undetectable.
    b. Tofacitinib: a washout period of at least 4 weeks prior to randomization.
    c. Cannot have failed both biologic and tofacitinib for UC.
    Note: No more than 51 subjects (50% of the total study population) with prior exposure to these therapies will be randomized into the study including no more than 20 subjects (20% of the total study population) with exposure to more than 1 biologic/tofacitinib therapy.
    5. If subjects are receiving the following treatments, they must be on a stable dose for at least 4 weeks prior to randomization:
    a. 5-Aminosalicylates (5-ASAs) (not exceeding 4.8 g per day).
    b. Oral corticosteroids (not exceeding prednisone 20 mg, budesonide 9 mg, or equivalent).
    c. 6-Mercaptopurine (6-MP) (any stable dose).
    d. Azathioprine (AZA) (any stable dose).
    e. Methotrexate (MTX) (any stable dose).
    6. If subjects are receiving bile-salt sequestrant, they must be on a stable dose for at least 3 months prior to randomization.
    7. If subjects are receiving any nonprohibited medications, they must agree to maintain stable doses of concomitant medications for UC until the end of the safety follow-up period.
    8. Unlikely to conceive.
    9. Women of childbearing potential (WOCBP) must have a negative pregnancy test at screening and at the randomization visit prior to the first dose of study drug.
    10. Able to participate fully in all aspects of this clinical trial.
    11. Written informed consent must be obtained and documented.
    E.4Principal exclusion criteria
    Exclusion criteria (subjects who exhibit any of the following criteria are to be excluded from the study):
    1. A diagnosis of Crohn’s disease (CD), indeterminate colitis, or presence or history of fistula with CD.
    2. Disease activity limited to distal 15 cm (proctitis).
    3. Current evidence of toxic megacolon, abdominal abscess, symptomatic colonic stricture, or stoma.
    4. History or current evidence of colonic dysplasia or adenomatous colonic polyps.
    5. Current bacterial or parasitic pathogenic enteric infection, including Clostridium difficile; known active cytomegalovirus infection; known infection with hepatitis B or C virus; known infection with human immunodeficiency virus; infection requiring hospitalization or intravenous (IV) antimicrobial therapy, or opportunistic infection within 6 months prior to screening; any infection requiring antimicrobial therapy within 2 weeks prior to screening; history of more than 1 episode of herpes zoster or any episode of disseminated zoster.
    6. A positive diagnostic tuberculosis (TB) test at screening (defined as a positive QuantiFERON test). In cases where the QuantiFERON test is indeterminate, the participant may have the test repeated once and if their second test is negative they will be eligible. In the event a second test is also indeterminate, or QuantiFERON is unavailable, the investigator has the option to perform a purified protein derivative (PPD) skin test. If the PPD reaction is < 5 mm, then the subject is eligible. If the reaction is ≥ 5 mm, or PPD testing is not done, the subject is not eligible. An exception is made for subjects with a history of latent TB who are currently receiving treatment for latent TB, will initiate treatment for latent TB before the first dose of study treatment, or have documentation of completing appropriate treatment for latent TB within 3 years prior to the first dose of study treatment).
    7. Live virus vaccination within 1 month prior to screening.
    8. Treatment with sirolimus, cyclosporine, mycophenolate, or tacrolimus within 8 weeks prior to randomization.
    9. Treatment with IV corticosteroids, rectal corticosteroids, or rectal 5-ASA within 4 weeks prior to randomization.
    10. Fecal microbiota transplantation within 1 month prior to screening.
    11. A concurrent clinically significant, serious, unstable, or uncontrolled underlying cardiovascular, pulmonary, hepatic, renal, gastrointestinal, genitourinary, hematological, coagulation, immunological, endocrine/metabolic, or other medical disorder that, in the opinion of the investigator, might confound the study results, pose additional risk to the subject, or interfere with the subject’s ability to participate fully in the study.
    12. Known primary or secondary immunodeficiency.
    13. History of myocardial infarction, unstable angina, transient ischemic attack, decompensated heart failure requiring hospitalization, congestive heart failure (New York Heart Association Class 3 or 4), uncontrolled arrhythmias, cardiac revascularization, stroke, uncontrolled hypertension, or uncontrolled diabetes within 6 months of screening.
    14. Clinically meaningful laboratory abnormalities at screening that would affect subject safety, as determined and documented by the investigator.
    15. Pregnant or lactating females.
    16. Any surgical procedure requiring general anesthesia within 1 month prior to screening, or planned elective surgery during the study.
    17. History of malignant neoplasms or carcinoma in situ within 5 years prior to screening.
    18. Current or recent history of alcohol dependence or illicit drug use that, in the opinion of the investigator, may interfere with the subject’s ability to comply with the study procedures.
    19. Mental or legal incapacitation or a history of clinically significant psychiatric disorders at the time of screening visit that would impact the ability to participate in the trial according to the investigator.
    20. Unable to attend study visits or comply with procedures.
    21. Concurrent participation in any other interventional study or received any investigational therapy within 1 month of randomization.
    22. Previous exposure to AMT-101 or recombinant human interleukin-10 (rhIL-10).
    23. A known hypersensitivity to AMT-101 or its excipients.
    24. Current treatment with antimotility medications or antidiarrheals (except for bile-salt sequestrants).
    E.5 End points
    E.5.1Primary end point(s)
    Mean change in MES from baseline to Week 12


    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 12
    E.5.2Secondary end point(s)
    Secondary Efficacy Endpoints:
    - Endoscopic remission rate at Week 12 (defined as a MES of 0 or 1)
    - Endoscopic response rate at Week 12 (defined as a decrease from baseline in MES of at least 1 point)
    - Mucosal healing rate at Week 12 (defined as MES of 0 or 1 and a Geboes Histologic Index score of ≤ 3.1)
    - Histologic remission rate at Week 12 (defined as Geboes Histologic Index score of ≤ 2B.0; or Robarts Histopathology Index [RHI] ≤ 3 with subscores of 0 for lamina propria neutrophils and 0 for neutrophils in epithelium)
    - Clinical remission rate at Week 12 (defined as total MCS ≤ 2 with all subscores ≤ 1)
    - Clinical response rate at Week 12 (defined as decrease from baseline in MCS of at least 3 points and at least 30%, with an accompanying decrease in the subscore for rectal bleeding of at least 1 point or an absolute subscore for rectal bleeding of 0 or 1)
    - Mean change in partial MCS from baseline to Weeks 2, 6, and 12
    - Mean change in Mayo rectal bleeding subscore from baseline to Weeks 2, 6, and 12
    - Mean change in Mayo stool frequency subscore from baseline to Weeks 2, 6, and 12
    - Proportion of subjects with a Geboes Histologic Index score ≤ 3.1 at Week 12
    - Mean change in RHI scores from baseline to Week 12
    - Mean change in fecal calprotectin from baseline to Weeks 2, 6, and 12
    - Mean change in high-sensitivity C-reactive protein (hs CRP) from baseline to Weeks 2, 6, and 12
    - Clinical remission rate at Week 12 (alternative definition of Mayo stool frequency subscore of 0 or 1 and Mayo rectal bleeding subscore of 0 and MES of 0 or 1)

    Secondary Safety Endpoints:
    - Frequency and severity of adverse events (AEs) compared to placebo
    - Changes in clinical chemistry and hematology from baseline
    - Results of vital signs and physical examination
    - Electrocardiogram (ECG) findings

    Secondary PK Endpoints:
    - Concentrations of AMT-101, AMT-101 antidrug antibodies (ADAs), and total IL-10 in serum

    Secondary HRQOL Endpoints:
    - Mean change in Symptoms and Impacts Questionnaire for UC (SIQ-UC) from baseline to Week 12
    - Mean change in Inflammatory Bowel Disease Questionnaire (IBDQ) score from baseline to Week 12, comparing AMT-101 to placebo
    E.5.2.1Timepoint(s) of evaluation of this end point
    Weeks 2, 6, and 12
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA37
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Belarus
    Belgium
    Bulgaria
    Canada
    France
    Georgia
    Germany
    Hungary
    India
    Italy
    Kazakhstan
    Moldova, Republic of
    Netherlands
    Poland
    Romania
    Russian Federation
    Serbia
    Switzerland
    Ukraine
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months9
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months2
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 87
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 15
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state20
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 47
    F.4.2.2In the whole clinical trial 102
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Once clinical trial participants have completed the 4 week follow-up visit, the participants will no longer receive study drug. The study doctor will talk to them about how best to continue their medical care.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-11-19
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-02-11
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2023 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA